9 active not recruiting, 9 recruiting, 8 terminated, 6 completed. 31 Phase 1, 19 Phase 2.
Follow Recurrent Myelodysplastic Syndrome: new trials by email Literature Review of Recurrent Myelodysplastic Syndrome trials Research Report on Recurrent Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Recruiting | National Cancer Institute (NCI) | 54 | 2025-08-15 | 2026-10-01 |
| Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2025-06-07 | 2025-05-25 | |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 20 | 2025-04-25 | 2026-10-20 |
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2025-03-12 | 2026-10-16 |
| DR-18 to Prevent or Treat Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse After Hematopoietic Cell Transplantation, the DR. DREAM Trial Decoy-resistant interleukin-18, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Suspended | Fred Hutchinson Cancer Center | 40 | 2024-09-23 | 2026-08-10 |
| Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane Cytarabine, Fludarabine, Leucovorin - Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2023-10-10 | 2026-06-02 |
| Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome Navitoclax, Venetoclax, Decitabine - Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome | Phase 1 | Completed | Thomas Jefferson University | 6 | 2023-01-12 | 2026-05-19 |
| Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Omacetaxine Mepesuccinate, Venetoclax - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Biphenotypic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 24 | 2021-12-17 | 2025-11-03 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Terminated | Northwestern University | 2 | 2020-12-21 | 2026-06-01 |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Venetoclax - Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2020-09-04 | 2026-06-05 |
| A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Canakinumab - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 76 | 2020-08-25 | 2026-05-20 |
| Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Biospecimen Collection, Bone Marrow Aspiration, Olaparib - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2020-08-04 | 2026-09-10 |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Azacitidine, Trametinib, Venetoclax - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 21 | 2020-07-21 | 2025-04-22 |
| Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Azacitidine, Quizartinib - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2020-07-21 | 2026-10-05 |
Showing 20 of 38. Sign in to see all of them.
Myelodysplastic Syndromes (38) · Leukemia, Myeloid, Acute (31) · Leukemia, Myelomonocytic, Chronic (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Biphenotypic, Acute (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Myeloproliferative Disorders (6) · Hematologic Neoplasms (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Myelodysplastic-Myeloproliferative Diseases (4) · Blast Crisis (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (3) · Hodgkin Disease (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3)
Bone Marrow Diseases (38) · Hematologic Diseases (38) · Hemic and Lymphatic Diseases (38) · Neoplasms (38) · Neoplasms by Histologic Type (38) · Leukemia, Myeloid (37) · Leukemia (36) · Disease Attributes (19) · Pathologic Processes (19) · Pathological Conditions, Signs and Symptoms (19) · Chronic Disease (18) · Myelodysplastic-Myeloproliferative Diseases (13) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Leukemia, Lymphoid (12)
Specimen Handling (11) · venetoclax (11) · Azacitidine (10) · Cytarabine (8) · Injections (7) · Biopsy (6) · Decitabine (6) · fludarabine (6) · CTLA-4 Antigen (4) · Cyclophosphamide (4) · Filgrastim (4) · Granulocyte Colony-Stimulating Factor (4) · Ipilimumab (4) · fludarabine phosphate (4) · quizartinib (4)
M.D. Anderson Cancer Center (16) · National Cancer Institute (NCI) (8) · Fred Hutchinson Cancer Center (5) · City of Hope Medical Center (4) · Mayo Clinic (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Thomas Jefferson University (1) · Vanderbilt-Ingram Cancer Center (1)
United States (36) · Canada (1)
Guillermo Garcia-Manero (4) · Elizabeth Krakow (3) · Guillermo M Bravo (2) · Musa Yilmaz (2) · Betul Oran, MD (1) · Courtney DiNardo, MD (1) · Evan C Chen (1) · Filippo Milano (1) · Gautam Borthakur (1) · Gina Keiffer, MD (1) · Guillaume Richard-Carpentier (1) · Jacqueline S Garcia (1) · Jithma P. Abeykoon, MD (1) · Katherine G Tarlock (1) · Keri R Maher (1)
PMID 27410923, PMID 32478814, PMID 33208914, PMID 33720354, PMID 36063832, PMID 36706355, PMID 36841758, PMID 37611156, PMID 38683966, PMID 38744144, PMID 39537648, PMID 39821392, PMID 39863139, PMID 40979071, PMID 42013378
P30CA033572 (4), UM1CA186709 (3), P30CA015704 (2), UM1CA186644 (2), P30CA006516 (1), P30CA060553 (1), R01CA183559 (1), U01CA062490 (1), UM1CA186689 (1), UM1CA228823 (1)